Patents Assigned to Daewoong Co., Ltd.
-
Patent number: 11185503Abstract: A stable liquid composition comprising a botulinum toxin as an active ingredient is described, which is ready-to-use without the need for a reconstitution process, and thus, it is possible to improve user's convenience, and reduce a deviation of botulinum toxin activity due to dilution errors in the reconstitution process. Further, the liquid composition efficiently prevents the botulinum toxin from aggregating even at a low botulinum toxin concentration to thereby have extremely excellent storage stability, and efficiently prevents adsorption of the botulinum toxin to a container, thereby constantly maintaining an activity of the botulinum toxin for each batch or for each liquid vial.Type: GrantFiled: October 17, 2017Date of Patent: November 30, 2021Assignee: DAEWOONG CO., LTD.Inventors: Hyeona Yim, Cheong-Sei Kim
-
Patent number: 10619143Abstract: The present invention relates to a method for producing a botulinum toxin comprising: (a) treating a culture of a botulinum toxin-producing strain with acid to form a botulinum toxin-containing precipitate; (b) adding a buffer to the botulinum toxin-containing precipitate of step (a), followed by clarification by at least one method selected from the group consisting of depth filtration (DF), microfiltration (MF), ultrafiltration (UF), sterile filtration, membrane chromatography (MC) and centrifugation; (c) subjecting the botulinum toxin-containing solution of step (b) to UF diafiltration, ammonium sulfate precipitation or hydrochloric acid precipitation, and then diluting a retentate resulting from the UF diafiltration in a buffer or dissolving a precipitate resulting from the ammonium sulfate precipitation or hydrochloric acid precipitate in a buffer; and (d) subjecting the retentate dilution, ammonium sulfate precipitate solution or hydrochloric acid precipitate solution of step (c) to anion-exchange chromType: GrantFiled: November 23, 2016Date of Patent: April 14, 2020Assignee: DAEWOONG CO., LTD.Inventors: Kyoung-Yun Kim, Chung Sei Kim, Myung Seob Kim, Hye-Young Sul
-
Patent number: 10465179Abstract: The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is about 1.5-2 times higher than that in the medium that is in current use. In addition, when botulinum toxin is produced by culturing the bacterium in the medium, infection with transmissible spongiform encephalopathy (TSE) or the like can be prevented by blocking introduction of animal-derived components.Type: GrantFiled: February 9, 2018Date of Patent: November 5, 2019Assignee: DAEWOONG CO., LTD.Inventors: Kyoung-Yun Kim, Hye-Young Sul, Kyoung-Min Min
-
Patent number: 10308923Abstract: The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises a porcine peptone and at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones, porcine peptones and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.Type: GrantFiled: April 28, 2016Date of Patent: June 4, 2019Assignee: DAEWOONG CO., LTD.Inventors: Kyoung-Yun Kim, Hye-Young Sul, Kyoung-Min Min
-
Patent number: 10117927Abstract: The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises a casein hydrolysate and at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones, casein hydrolysates and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is higher than that in each of the medium that is in current use and the medium comprising plant-derived peptones alone. In addition, when the medium of the present invention is used, a high concentration of botulinum toxin can be produced by culturing the bacterium in a safe manner.Type: GrantFiled: April 28, 2016Date of Patent: November 6, 2018Assignee: DAEWOONG CO., LTD.Inventors: Kyoung-Yun Kim, Hye-Young Sul, Kyoung-Min Min
-
Patent number: 9926549Abstract: The present invention relates to a medium composition for production of botulinum toxin and, more particularly, to a medium composition for culture of Clostridium sp. capable of producing botulinum toxin. The medium composition of the present invention comprises at least one plant-derived peptone selected from the group consisting of a garden pea hydrolysate, a cotton seed hydrolysate and a wheat gluten hydrolysate. When the medium according to the present invention, which contains plant-derived peptones and minerals, is used for culture of Clostridium botulinum, the growth rate of the bacterium in the medium is about 1.5-2 times higher than that in the medium that is in current use. In addition, when botulinum toxin is produced by culturing the bacterium in the medium, infection with transmissible spongiform encephalopathy (TSE) or the like can be prevented by blocking introduction of animal-derived components.Type: GrantFiled: April 28, 2016Date of Patent: March 27, 2018Assignee: DAEWOONG CO., LTD.Inventors: Kyoung-Yun Kim, Hye-Young Sul, Kyoung-Min Min
-
Patent number: 9918937Abstract: The present invention provides a pharmaceutical composition in a powder form for providing wound protection, hemostasis, or anti-adhesion in the gastrointestinal tract, which comprises a certain mucoadhesive polymer; and a certain hygroscopic agent.Type: GrantFiled: October 31, 2013Date of Patent: March 20, 2018Assignees: DAEWOONG CO., LTD., CG BIO CO., LTD., UTAH-INHA DDS & ADVANCED THERAPEUTICS RESEARCH CENTERInventors: In-Ae Kim, Sang-Hee Kim, Ji-Hoon Jung, Hee-Chul Chang, Jin-Hee Maeng, Su-Geun Yang, Don-Haeng Lee, Kyung-Hyun Min
-
Patent number: 9540378Abstract: The present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt as an active ingredient. And also, the present invention provides a cosmetic composition for improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt; and a food (i.e., a functional food) for preventing or improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt.Type: GrantFiled: April 12, 2013Date of Patent: January 10, 2017Assignee: DAEWOONG CO., LTD.Inventors: Gyeong-Sug Nam, Se-Joon Yoon, Ok-Gyung Choi, Jin-Pyo Kim, Soo-Jin Choi, Hyong-Jin Park
-
Patent number: 9512418Abstract: A method of making botulinum toxin comprises treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and purifying the botulinum toxin by anion exchange chromatography. The use of the method makes it possible to produce a high-purity botulinum toxin by a simple process. The botulinum toxin produced by the method has high purity, and thus has an increased ability to act in a local area. Thus, the systemic circulation of the botulinum toxin is reduced to increase the safety. Accordingly, the botulinum toxin can be used for treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy.Type: GrantFiled: May 7, 2014Date of Patent: December 6, 2016Assignee: Daewoong Co., Ltd.Inventors: Chung Sei Kim, Kwan Young Song, Kyoung Min Min, Yeong Duk An
-
Publication number: 20150352049Abstract: The present invention provides a pharmaceutical composition in a powder form for providing wound protection, hemostasis, or anti-adhesion in the gastrointestinal tract, which comprises a certain mucoadhesive polymer; and a certain hygroscopic agent.Type: ApplicationFiled: October 31, 2013Publication date: December 10, 2015Applicants: DAEWOONG CO., LTD., CG BIO CO., LTD., UTAH-INHA DDS & ADVANCED THERAPEUTICS RESEARCH CENTERInventors: In-Ae KIM, Sang-Hee KIM, Ji-Hoon JUNG, Hee-Chul CHANG, Jin-Hee MAENG, Su-Geun YANG, Don-Haeng LEE, Kyung-Hyun MIN
-
Patent number: 9199965Abstract: Disclosed herein are novel benzoimidazole derivatives functioning as antagonists to vanilloid receptor-1, and a pharmaceutical composition comprising the same. They are useful in preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraines, arthralgia, neuropathy, nerve injury, diabetic neuropathy, neurological illness, neurodermatitis, strokes, bladder hypersensitivity, irritable bowel syndrome, respiratory disorders such as asthma, chronic obstructive pulmonary disease, etc., burns, psoriasis, itching, vomiting, irritation of the skin, eyes, and mucous membranes, gastric-duodenal ulcers, inflammatory intestinal diseases, and inflammatory diseases.Type: GrantFiled: January 27, 2006Date of Patent: December 1, 2015Assignee: Daewoong Co., Ltd.Inventors: Ji Duck Kim, Hong Chul Yoon, In Woo Kim, Hyae Jung Hyun
-
Publication number: 20150337281Abstract: A method of making botulinum toxin comprises treating a culture of a botulinum toxin-producing strain with acid to precipitate a botulinum toxin; adding buffer to the precipitated botulinum toxin, followed by treatment with a protease inhibitor and nuclease, thereby extracting the botulinum toxin; treating the extracted botulinum toxin with acid to precipitate the botulinum toxin and dissolving the precipitate in buffer; and purifying the botulinum toxin by anion exchange chromatography. The use of the method makes it possible to produce a high-purity botulinum toxin by a simple process. The botulinum toxin produced by the method has high purity, and thus has an increased ability to act in a local area. Thus, the systemic circulation of the botulinum toxin is reduced to increase the safety. Accordingly, the botulinum toxin can be used for treatment of neuromuscular disorders, removal of wrinkles, and treatment of spastic hemiplegia and cerebral palsy.Type: ApplicationFiled: May 7, 2014Publication date: November 26, 2015Applicant: Daewoong Co., Ltd.Inventors: Chung Sei KIM, Kwan Young SONG, Kyoung Min MIN, Yeong Duk AN
-
Patent number: 9155697Abstract: Provided is a liquid composition for treating stomatitis, the liquid composition including: an epidermal growth factor; an adhesive polymer; and at least one stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, histidine, lysine and inorganic acid salts thereof, arginin and inorganic acid salts thereof, and dextran. The liquid composition includes a stabilizer selected from EDTA (or salts thereof) and a certain amino acid (or inorganic acid salts thereof) and thus, physicochemical and biological stability of the epidermal growth factor can be substantially increased. Thus, the liquid composition can be stored and distributed for a long period of time. The stabilized composition includes an adhesive polymer, and thus, when ejected in a spray form in the mouth of a user, the liquid composition can be quickly attached to an inflammation site and exhibits effectiveness for a long period of time.Type: GrantFiled: October 9, 2007Date of Patent: October 13, 2015Assignee: DAEWOONG CO., LTD.Inventors: Sun-Hee Kim, Sang-Kil Lee, Chae-Ha Yoon, Sun-Mee Yang, Sang-Hyun Nam, Kyeong-Sun Shin, Seung-Kook Park, Sang-Wook Lee
-
Publication number: 20150079157Abstract: The present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt as an active ingredient. And also, the present invention provides a cosmetic composition for improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt; and a food (i.e., a functional food) for preventing or improving atopic dermatitis comprising 2-amino-1,9-dimethylpurin-6-one or its pharmaceutically acceptable salt.Type: ApplicationFiled: April 12, 2013Publication date: March 19, 2015Applicant: DAEWOONG CO., LTD.Inventors: Gyeong-Sug Nam, Se-Joon Yoon, Ok-Gyung Choi, Jin-Pyo Kim, Soo-Jin Choi, Hyong-Jin Park
-
Patent number: 8685440Abstract: The present invention relates to a nanoliposome comprising a liposome membrane containing esterified lecithin, and one or more physiologically active ingredients included in inner space of the liposome membrane; a method for preparing the same; and a composition for preventing or treating skin diseases, comprising the same. The nanoliposome according to the present invention has long-term stability and uniformity, and so can be used to prepare a composition for skin having excellent moisturizing and penetrating properties, such as cosmetics, medicament for treating skin diseases, or the like. In particular, the present composition for preventing or treating skin diseases comprises epidermal growth factor included in the nanoliposome, thereby showing an excellent effect of stimulating skin-penetration and good pharmaceutical stability.Type: GrantFiled: August 1, 2007Date of Patent: April 1, 2014Assignee: Daewoong Co., LtdInventors: Joon Pio Hong, Sang Kil Lee, Won Chul Kim, Chae Ha Yoon, Sang Wook Lee, Kyeong Sun Shin, Seung Kook Park
-
Patent number: 8409586Abstract: Disclosed herein is a stable liquid formulation comprising human growth hormone; L-lysine, L-arginine or polyethylene glycol 300; and poly(oxyethylene) poly(oxypropylene) copolymer, polyethylene glycol-15 polyoxystearate or polyethylene glycol-35 castor oil.Type: GrantFiled: July 6, 2006Date of Patent: April 2, 2013Assignee: Daewoong Co., Ltd.Inventors: Sun hee Kim, Yo kyung Chung, Jae young Chang, Sang kil Lee, Min suk Lee, Seung kook Park
-
Publication number: 20110192396Abstract: Provided is a pharmaceutical composition for preventing or treating mucus hypersecretion in airways or chronic obstructive pulmonary diseases (COPDs), the pharmaceutical composition including an epidermal growth factor (EGF) and a pharmaceutically acceptable carrier. In addition, a combined preparation capable of respectively administering the pharmaceutical composition and chemotherapeutics is provided.Type: ApplicationFiled: October 9, 2009Publication date: August 11, 2011Applicant: DAEWOONG CO., LTD.Inventors: Sun Mee Yang, Kwon Jo Lim, Hyun Jin Park, Il Hwan Kim, Sang Ho Lee, Jong Wook Lee
-
Patent number: 7811786Abstract: Disclosed are a method of producing a target protein in a biologically-active, soluble form in prokaryotic cells and polycistronic vectors therefor.Type: GrantFiled: June 11, 2004Date of Patent: October 12, 2010Assignee: Daewoong Co., Ltd.Inventors: Bong Yong Lee, Seung Kook Park, Shin Hye Park, Oh Byung Kwon, Chae Ha Yoon, Young Ju Kim, Song Young Kim, Kyung Hyun Min, Yoon Seok Lee, Tae Hee Lee, Tai Young Koo
-
Publication number: 20100255503Abstract: Disclosed herein are diagnostic markers CTHRC1, CANP and KIAA0101, which are overexpressed specifically in breast or colorectal cancer. A method for diagnosing the cancer by detecting the markers, and a method for preventing or treating by inhibiting the expression and activity of the markers are also disclosed.Type: ApplicationFiled: January 20, 2010Publication date: October 7, 2010Applicant: DAEWOONG CO., LTD.Inventors: InKyung SHIN, Hyun jin PARK, Joo young CHOI, Hyae Jung HYUN, Kyeong-Sun SHIN, Seung kook PARK
-
Publication number: 20100035809Abstract: Provided is a liquid composition for treating stomatitis, the liquid composition including: an epidermal growth factor; an adhesive polymer; and at least one stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, histidine, lysine and inorganic acid salts thereof, arginin and inorganic acid salts thereof, and dextran. The liquid composition includes a stabilizer selected from EDTA (or salts thereof) and a certain amino acid (or inorganic acid salts thereof) and thus, physicochemical and biological stability of the epidermal growth factor can be substantially increased. Thus, the liquid composition can be stored and distributed for a long period of time. The stabilized composition includes an adhesive polymer, and thus, when ejected in a spray form in the mouth of a user, the liquid composition can be quickly attached to an inflammation site and exhibits effectiveness for a long period of time.Type: ApplicationFiled: October 9, 2007Publication date: February 11, 2010Applicant: DAEWOONG CO., LTD.Inventors: Sun-Hee Kim, Sang-Kil Lee, Chae-Ha Yoon, Sun-Mee Yang, Sang-Hyun Nam, Kyeong-Sun Shin, Seung-Kook Park, Sang-Wook Lee